Contents

Preface .......................... v
Contributors .............................................. ix
1 QSAR Methods ............................... 1
   Giuseppina Gini

PART I  MODELING A PHARMACEUTICAL IN THE HUMAN BODY

2 In Silico 3D Modeling of Binding Activities ............................ 23
   Stefano Moro, Mattia Sturlese, Antonella Ciancetta, and Matteo Floris

3 Modeling Pharmacokinetics .............................................. 37
   Frederic Y. Bois and Céline Brochot

4 Modeling ADMET .................................................. 63
   Jayeeta Ghosh, Michael S. Lawless, Marvin Waldman, Vijay Gombar,
   and Robert Fraczkiewicz

PART II  THE APPLICATIONS OF IN SILICO MODELS
FOR THE DIFFERENT ENDPOINTS

5 In Silico Prediction of Chemically Induced Mutagenicity:
   How to Use QSAR Models and Interpret Their Results ............ 87
   Enrico Mombelli, Giuseppa Raitano, and Emilio Benfenati

6 In Silico Methods for Carcinogenicity Assessment ....................... 107
   Azadi Golbamaki and Emilio Benfenati

7 VirtualToxLab: Exploring the Toxic Potential of Rejuvenating
   Substances Found in Traditional Medicines .......................... 121
   Martin Smieško and Angelo Vedani

8 In Silico Model for Developmental Toxicity: How to Use QSAR Models
   and Interpret Their Results ......................................... 139
   Marco Marzo, Alessandra Roncaglioni, Sunil Kulkarni,
   Tara S. Barton-Maclaren, and Emilio Benfenati

9 In Silico Models for Repeated-Dose Toxicity (RDT): Prediction
   of the No Observed Adverse Effect Level (NOAEL) and Lowest
   Observed Adverse Effect Level (LOAEL) for Drugs .................. 163
   Fabiola Pizzo and Emilio Benfenati

10 In Silico Models for Acute Systemic Toxicity .......................... 177
    Julien Burton, Andrew P. Worth, Ivanka Tsakovska,
    and Antonia Diukendjieva

11 In Silico Models for Hepatotoxicity .................................. 201
    Mark Hewitt and Katarzyna Przybylak

serena.manganelli@marionegri.it
### Contents

12 In Silico Models for Ecotoxicity of Pharmaceuticals
   *Kunal Roy and Supratik Kar*

   237

13 Use of Read-Across Tools
   *Serena Manganelli and Emilio Benfenati*

   305

---

#### PART III  THE SCIENTIFIC AND SOCIETY CHALLENGES

14 Adverse Outcome Pathways as Tools to Assess Drug-Induced Toxicity
   *Mathieu Vinken*

   325

15 A Systems Biology Approach for Identifying Hepatotoxicant Groups
   Based on Similarity in Mechanisms of Action and Chemical Structure
   *Dennie G.A.J. Hebels, Axel Rasche, Ralf Herwig, Gerard J.P. van Westen, Danyel G.J. Jennen, and Jos C.S. Kleinjans*

   339

16 In Silico Study of In Vitro GPCR Assays by QSAR Modeling
   *Kamel Mansouri and Richard S. Judson*

   361

17 Taking Advantage of Databases
   *Glenn J. Myatt and Donald P. Quigley*

   383

18 QSAR Models at the US FDA/NCTR
   *Huixiao Hong, Minjun Chen, Hui Wen Ng, and Weida Tong*

   431

19 A Round Trip from Medicinal Chemistry to Predictive Toxicology
   *Giuseppe Felice Mangiatordi, Angelo Carotti, Ettore Novellino, and Orazio Nicolotti*

   461

20 The Use of In Silico Models Within a Large Pharmaceutical Company
   *Alessandro Brigo and Wolfgang Muster*

   475

21 The Consultancy Activity on In Silico Models for Genotoxic Prediction of Pharmaceutical Impurities
   *Manuela Pavan, Simona Kovarich, Arianna Bassan, Lorenza Broccardo, Chihae Yang, and Elena Fioravanzo*

   511

Index

531